Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for ...
Serum T3 measurement is useful for monitoring compliance with L-T3 suppression therapy prior to 131I scan for DTC. Serum T3 measurement is useful for distinguishing mild (subclinical ...
GlobalData on MSN1mon
Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec execHowever, only two have been approved by the US Food and Drug Administration (FDA) – Spectrum Pharmaceutical’s Zevalin ...
breastfeeding is to be totally avoided after 131I administration for therapeutic purpose. » Can patient protection be considered in the selection of radiopharmaceuticals? Yes. If more than one ...
Using a murine leukemia model, he is testing 90Y, 211At and 131I bound antibodies that recognize a molecule called CD45 that is found on most blood cells, including leukemia cells. He is working to ...
在实际工作中还应考虑以下具体问题： （1）关于体外测量 在监测g辐射核素时，通常遇到的是核裂变产物和中子活化产物，例如131I、137Cs、60Co等。在测量这些核素时，对测量装置的灵敏度要求 ...
围绕肿瘤诊疗一体化的治疗理念，远大医药目前在核药抗肿瘤诊疗板块已储备总计12款创新产品，涵盖68Ga、177Lu、131I、90Y、89Zr在内的5种放射性核素 ...
2024年11月1日，泽璟制药披露接待调研公告，公司于10月28日接待广发证券、浙商证券、信达证券、华安证券、华西证券等127家机构调研。公告显示，泽璟制药参与本次接待的人员共1人，为公司主要管理人员。调研接待地点为电话会议。据了解，泽璟制药第三季度营业收入1.43亿元，同比增长130.67%；前三季度营业收入3.84亿元，同比 ...
If needed, Amylovis has the advantage of being versatile in radiolabeling, and can be labeled with different types of radionuclide, both gamma ray emitters (99mTc, 123I or 131I) and positron ...
（以下内容从上海证券《医药生物行业周报：Pluvicto放量迅速，核药赛道空间大》研报附件原文摘录） 主要观点 Pluvicto放量迅速，2024年前三季度收入已超过10亿美元 10月29日，诺华公布2024Q3业绩，第三季度收入128.23亿美元，同比增长10%。前9个月总收入371.64亿美元，同比增长11%。Pluvicto继续保持了亮眼的表现，前三季度收入10.41亿美元（+47%）。Pl ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback